Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

Orion Pharma

Status and phase: Completed; Phase 2

Conditions: Coronary Heart Disease

Treatments: Drug: levosimendan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00130871

3001079

Details and patient eligibility

About

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Full description

Levosimendan or placebo infusion is started at the time of induction of anesthesia.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Three vessel coronary artery disease.
• Indication for on-pump coronary artery bypass surgery.
• Ejection fraction below 50%

Exclusion criteria

• Indication for any cardiac valve surgery
• Previous coronary artery bypass surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind